Note: Descriptions are shown in the official language in which they were submitted.
R'O 95112385 PCT/US9~/12351
-1- , =~1?544
Description
MICROPARTICULAR PHARMACEV11GL COMPOSITIONS 1N MICELLAR FORM
Background of the Invent~nn
The present invention relates generally to
pharmaceutical compositions comprising microparticles
suspended in micelle. More particularly, the
microparticles comprise at least one pharmaceutically-
active agent, at least one water soluble or miscible
phospholipid, at least one lipid soluble or miscible
phospholipid, at least one water soluble or miscible
sterol, at least one non-ionic surfactant having an HLB
value of about 15 or greater, and at least one non-
ionic surfactant having an HLB value of about 6 or
less, and the microparticles are suspended in micelle
in at least one water soluble or miscible fatty acid
having a chain length of C14 or less. This invention
also relates to a method of preparing such
compositions, methods of therapeutically treating
various illnesses and conditions with such
compositions, and methods of delivery of such
compositions to human beings.
By binding a pharmaceutically-active agent (e. g.
insuliny in accordance with this invention, enhanced
bioavailability and bioactivity results from the bound
pharmaceutically-active agent. For example, after oral
or transdermal administration of the embodiment of this
invention where insulin is the pharmaceutically-active
agent, the composition is channeled into the liver,
where the initially protected insulin is gradually
released, mimicking an endogenously secreted insulin as
found in human beings. An exogenous insulin, for
example, has been successfully delivered by routes
other than parenteral injection. The compositions of
WO 95112385 _ PC1YUS94112351
;. ;;
_2-
this invention may be applied by rectal, buccal,
sublingual, intranasal, intrapulmonic, ocular or by
other means of administration for management of
disorders, for example diabetes mellitus. The
compositions m$y be delivered selectively, after
parenteral infusion, oral, transdermal, or other means
of administration to achieve precise targeting of the
pharmaceutically active agent to a given organ or
tissues as a slow, controlled release-dosage
formulation. The invention may be useful for, but not
limited to, delivering pharmaceutically-active agents
which include peptides (e. g. insulin), glycoproteins
(e. g. erythropoietin), organic and inorganic chemicals
(e. g. glyburide or steroids), herbals (e. g. vinca
alkaloids), and other materials useful as
pharmaceutically active agents.
For example, diabetes mellitus is a chronic
disorder affecting carbohydrate, fat and protein
metabolism. It is generally characterized by high
blood sugar level (hyperglycemia) and sugar in urine
(glycosurea) from a defective or deficient insulin
secretory response. In the United States, over 10
million people are diagnosed as diabetics and this
figure is increasing annually at a rate of about 6%.
Two major variants of the disease exist. For about 10%
of diabetics, the disease onsets as a juvenile
insulinopenic diabetes requiring daily injection of
insulin (referred to herein as insulin dependent
diabetics or IDDM). The majority of diabetics are
adult-onsetting diabetics (referred to herein as non-
insulin dependent or NIDDM) for whom oral
antihyperglycemics may be introduced to control
hyperglycemia and glycosurea. Such compounds include
chlorpropamide, tolbutamide (the first generation group
of sulfonylureas), glyburide and glipizide (the second
generation group). The sulfonylureas are believed to
R'O 95/12385 _ PGTJU594/12351 .
3
h .:,f.,_
,r.,..3,
stimulate the beta cells of the pancreas, causing
secretion of an endogenous insulin, and are also known
to reduce hepatic production and to increase peripheral
muscular utilization of glucose.
Ultimately, however, sulfonylureas will become
less effective and eventually totally ineffective in
lowering blood.sugar in many long-term NIDDM patients,
thus requiring injections of insulin as well, which
causes restoration of the bioactivity of the sulfonyl
urea (e.g. glyburide). According to one embodiment of
the present invention, insulin-containing compositions
of this invention, glyburide-containing compositions of
this invention, and their combination markedly improved
the bioavailability and activity of glyburide and oral
insulin in NIDDM patents, who typically resist
commercial glyburide and thus require daily injections
of insulin.
Another embodiment of the present invention is
directed to trans-umbilico dermal (referred to herein
as TuD) delivery systems of the above-described
compositions in human beings. More specifically, the
TuD drug delivery system is concerned with well
protected pharmaceutically-active agent or agents
prepared in accordance with the compositions of this
invention which are channeled into the liver, Where the
protected agent is released at a slow controlled rate,
inducing the bioactivity of such compounds. In
accordance with the present invention, the composition
or compositions are applied on the dermal area of the
human navel, that is the falciform ligament
' (paraumbilical veins) and its related system. The
falciform ligament and Lig. teres in the liver, which
are connected to tributaries of the epigastric veins
and around the umbilicus, form anastomoses between the
portal and the systemic venous systems. The umbilical
foci is different from ordinary dermal layers. It is
WO 95112385 . PCT/US94112351
_4_
an artificially made scar tissue, having a thin
epidermal layer with a direct connection to the ,
falciform ligament (paraumbilical veins) and the
epigastric vein. After applying the compositions of ,
the present invention via the trans-umbilico-dermal
delivery system to the navel foci, the compositions are
rapidly and readily absorbed via the falciform
ligament, and distributed within the liver and the
systemic venous system. The trans-umbilico-dermal
delivery of compositions of the present invention may
also be employed as a means of targeting cancer
chemotherapeutics (e. g, doxorubicin) into the liver,
uterus, ovaries, lungs, the gastrointestinal system
including the stomach, rectum, colon, etc. as well as
other organs and systems.
By replacing inhibitors (e. g. nonulosaminic acid)
with potentiators (e. g. a triantennary galactose
terminated cholesterol), an affinity to the
macrophageal system may be modified and it is possible
to make compositions of this invention which can be
predominantly channeled into the liver and other
reticuloenthothelial systems (RES), thereby modifying
the bioactivity of the pharmaceutically active agents
employed while.the systemic blood concentrations of
such agents are kept at relatively low, non-toxic, non-
side effect-inducing levels. Such hepato-specific
delivery system-bound compositions may be given orally,
rectally, trans-umbilico-dermally, parenterally or by
other means. The therapeutic efficacy (i.e. the ratio
between the side effect or toxic dose over the
effective dose) of the agent may be increased by its
binding in accordance with this invention. This may be
exemplified as follows: disulfiram is biotransformed in
the liver, forming an active diethyl dithiocarbamic
acid; benzamidosalicylate forms amino-salicylic acid;
biguanide forms cycloguanil; diazepam forms oxazepam;
WO 95/12385 PCf/US94/1235I
imipramine forms desipramine; phenacetin is activated
in forming paracetamol; phenytoin forms di-
phenyluredoacetic acid, and so forth. Also, the
therapeutic effectiveness of pharmaceutically active
5 agents may be induced by their transportation into the
liver, where the agent or agents are actively
biotransformed into therapeutically effective agents.
For example, the antimalarial activity of primaquine as
a pharmaceutically active agent is increased by its
intrahepatic biotransformation into quinone derivatives
while the side.effects are reduced.
The present invention is dissimilar from other
types of drug or pharmaceutical agent delivery systems.
For example, compared to other routes, oral
administration of compositions of the present invention
containing insulin are more acceptable and convenient
for diabetics. More particularly, absorption of
insulin from the intestines to cause lowering of blood
glucose levels has been reported when pancreatic
enzymes are inactivated (Inouye, W.Y. et al. in Surg.
Forum 13:316 (1962); Danforth, E. et al. in
Endocrinology 65:118 (1959); and Crane, C.W. et al. in
Diabetes 17:625 (1968)). However, the absorption of
non-degradated insulin was found to be poor. To
promote absorption of the macromolecules (e. g. insulin)
from the intestinal membrane, surfactants,
triglycerides, and lipid-surfactant mixed micelles have
been reported with poor or unsatisfactory results
(MUranishi, S. et al. in J. Pharm. Dyn. 1:28 (1978); J.
Pharm. Dyn. 2:286 (1979); Int. J. Pharm. 4:219 (1980);
' Inouye et al., Danforth et al., and Crane et al.).
Insulin and a few adjuvants (anticholinergics)
' have been combined with a non-ionic surfactant (i.e.
BRIJI 98), causing absorption of insulin; however, the
minimum effective dose of insulin in human beings was
too large (Galloway, J.A. et al. in Diabetes 21:637
WO 95112385 ., PCTIUS94/12351
. r
~1~~~ ~ ;., .
(1972)). The non-ionic surfactant BRIJI 58 combined
with insulin was found to be effective in increasing
intestinal absorption of insulin, but the effective
dose of insulin required was too large (Meshia, M.S. et
al. in J. Pharm. Pharmacol. 33: 733 (1981)). After a
water-oil-water (w-o-w) emulsion form of insulin was
administered into a ligated jejunal pouch in rabbits,
less than 8% absorption of insulin was reported, which
was increased to about 58% of absorption of insulin
administered as w-o-w micelle into the ligated jejunal
pouch (Kawamori, R. and Shichiri, M. in Diabetes (1982)
in Int. Cong. Ser. 600:315 (1983)). An oral insulin in
nanoparticles was reported in Oppenheim, R.C. et al.,
Drug Dev. Ind. Pharm 8:531 (1982), but a large dose of
insulin was needed. (Galloway et al.; Meshia et al.;
Kawamon et al., Int. Cong. Ser. 600:315 (1983);
Oppenheim et al.).
U.S. Pat. 4,146,499 (Rosano) discloses several
methods for preparing oil-in-water (o-in-w) forms of
microemulsion systems by applying an amphiphatic
surfactant into the oil phase, and a second surfactant
having its HLB value above the primary surfactant into
the aqueous phase of water or buffer solutions. The oil
soluble substance is dissolved in the solvent (e.g
light mineral oil) having low boiling hydrocarbons
(e. g. hexane), halocarbons containing a hydroxy group
(e. g. carbon tetrachloride), and water immiscible
oxygenated hydrocarbons (e.g. diethyl ether). The
dispersion of the oils into the aqueous solvent
converts the lactescent in dispersion into a
microemulsion. No data on its biologically applicable
efficacy are given.
Although the oral insulin forms obtained from the
above-cited references may be absorbed from the
intestinal membrane with limited efficiency, they
apparently are inactivated at the liver and cleared by
N'O 95112385 . PCT/US94/12351
7 ,;
'. . ~ a
various macrophageal systems, which may include the
Peyer's patch, various circu3ating scavenger blood
cells, lymphoid tissues, the reticulo-endothelial
systems, and others.
U.S. Patent No. 4,579,730 (Kidron et al.)
discloses a.pharmaceutical composition for the oral
administration of insulin which comprises insulin, bile
salt or its derivatives and a protease-inhibitor. The
composition can be enterocoated not only to protect the
delivery system in the stomach but also to make the
mixture slow release within the intestinal tract, and
after its oral absorption from the intestinal membrane,
enable delivery through the portal vein into the liver.
The formulation disclosed in Kidron may not survive in
the liver, as there are no means of protecting the
system in the liver (other than the protease-inhibitor
added), and Kidron's sustained-releasing form for
insulin in the intestine would cause it to be too
slowly absorbed. Biological test results of the oral
insulin disclosed in Kidron were found to be poor and
even less active than some other systems of applying
surfactants, such as micelle, o-in-w emulsions and
others (Muranishi, S. et al.; Galloway, J.A. et al.;
Kawamori, R. et al.). In contrast, in the present
invention only nonionic surfactants are employed in
conjunction with the water soluble or miscible sterol
and phospholipid bound microparticles suspended in micelle.
Significantly altered pharmacokinetics and
efficacy of a polyglycol suspension of glyburide after
oral or intravenous infusion was reported by Roger,
H.J. et al. in Diabetologia 23:37 (1982). A micelle-
forming polymeric adriamycin was made by using
polyethyleneglycol and polyaspartic acid, which
prolonged the survival time of cancerous mice while
toxicity was reduced (the particle size was about 46 nm
measured by laser scattering). Also, the system
WO 95112385 . PCT/US94112351
decreased antigenicity and prolonged its half-life in
the circulating blood. It is also known that
polyethyleneglycol is a nontoxic, nonimmunogenic water
soluble and biodegrading polymer, as disclosed by
Yokoyama, M. et al: in Makromol. Chem. 8:431 (1987).
This system was intraperitoneally injected into the
mice. Water soluble and targetable polymeric drug
carriers based on N-(2-hydroxypropyl)methacryl-amide
(HPMA) were bound with, for example, 5-aminosalicylic
l0 acid and galactosamine as the targeting moiety to
cancer cells, as reported by Kopecek, J. in Advanced
Drug Deliv. System 4 (ed. by Anderson, J.M. et al., at
279-290 (1990)). In contrast, the present invention is
not used in conjunction with any polymeric or co-
polymeric systems, and is effective for oral or TuD
delivery of peptides.
Liposomes have been used as an oral delivery
system for insulin. However, liposomes have shown a
lack of dose-responsiveness, and inter- and intra-
patients variations in the bioavailability and efficacy
of insulin were noticed (Patel, H.M. et al. in FEBS
Letters 62:60 (1976); Dapergolas, G. et al. in Lancet
2:824 (1976)). A modified liposome and a multiple
emulsion has been disclosed in Eur. Pat. Appln. No.
0140085 (Yoshida). A drug containing lipid vesicle was
prepared by stir-mixing an aqueous solution with
phospholipids containing lipophilic surfactant. The
lipid vesicles were dispersed in a dispersion medium
and were freeze or spray dried (Patel et al.;
Dapergolas et al.).
Europ. Pat. Appl. No. 0277776 (Huang) discloses a '
solid core liposome obtained by encapsulating a polymer
mixture of emulsified warm (70°C) aqueous agarose and '
gelatin used as a topical or local administration as a
sustained release drug carrier for an enzyme or
peptide. This is similar to the system disclosed in
WO 95112385 PGTIUS94/12351
'~1 ~5 - -
U.S. Patent No. 5,250,236 (Gasco), discussed further
herein.
U.S. Paterit No. 4,536,324 (Fujiwara et al.)
discloses a lipovesicle form made by dispersing a
nonionic surfactant into a hydrophilic or hydrophobic
component in an isolated state from an aqueous
dispersion medium. The vesicle is formed by
polyoxyethylene castor oil ethers and polyoxyethylene
hardened castor oil ethers in the presence of sorbitan
polyesters of long chain (C14-C18) fatty acids. An oil
component of. cosmetics may be contained in the vesicle,
which has as its membrane component a lipophilic
surfactant.
U.S. Patent No. 4,348,384 (Horikoshi et al.)
discloses a pharmaceutical liposomal formulation
containing coagulation Factor-vIII or IX and a protease
inhibitor. The liposome forming materials were egg yolk
lecithin, phosphatidic acid or phosphatidylserine (to
improve the stability and forming ability of liposome),
cltiolesterol (to strengthen the liposomal membrane),
lyso-lecithin (to promote the fusion of the liposomal
membrane with the membrane of absorptional cells), and
phosphatidic acid (to enlarge the particle sizes of liposome).
However, Fujiwara et al.~s lipid vesicles and
Horikoshi et al.~s liposome are entirely different from
the phospholipid-bound pharmaceutically-active agents
in the form of microparticles suspended in micelle of
the present invention. Horikoshi et al. selected
negatively charged phosphatidic acid (referred to
herein as PA) or phosphatidylserine (referred to herein
as PS), which was bound with a cholesterol moiety.
These elements,together may possibly mechanically
stabilize and strengthen the liposomal membrane.
However, in the present invention, the pharmaceutically
active agent-containing microparticles are prepared by
using a water soluble or miscible phospholipid
WO 95/12385 . - PCTIU594112351
21"~5~199~ _lo_
(noncovalently bound with the agent) and then bound to
a water soluble or miscible sterol, in conjunction with
a lipid soluble or miscible phospholipid. For example,
in the present_invention a lysophospholipid (referred ,
to herein as lyso-PL) such as lyso-phosphatidylcholine
(referred to herein as lyso-PC) may be used to improve
the adherence of the microparticle to the membrane of
absorptive cells and to enable and induce an additive
effect with the surfactants in a physiological manner
without inducing any histopathological damage to
intestinal membranes, which are known to be induced by
lyso-PC at relatively higher concentrations, e.g. 0.01-
1 mM (Tagesson, C. et al. in Gut. 26:369 (1985)).
French Patent No. 85-06998 (Tressensj discloses a
multivesicular liposome where the lipid phase consists
of phosphatidylethanolamine (PE), cholesterol, PS,
trioleine in chloroform and ether, while the aqueous
phase contains an insulin - maltose solution. The
multivesicular.liposome was lyophilized and packed into
intestinal capsules. In contrast, in the present
invention the pharmaceutically active agent (e. g.
insulin) is reversibly bound and made into a micro-
particle comprising a phospholipid such as a
glycerophospholipid. The present invention is neither
a liposome nor a multivesicular liposome.
U.S. Patent No. 4,855,090 (Wallach) discloses
multilamellar lipid vesicles (liposomes) having a high
encapsulating mass and volume for hydrophilic or
lipophilic materials. The lipophilic phase contains a
surfactant (e. g. polyoxyethylene fatty ethers,
polyoxyethylene cetyl ether, lauryl ether) with a
sterol (e. g. cholesterol) and a charge producing
amphiphile having a higher melting point than that of
the surfactants. No biological data are given to
indicate any efficacy of the claimed formulae in
delivering peptides.
R'O 95/12385 PCT/US94/12351
-11- ,.
European Patent Appl. No. 143,949 (Nakagama
et al.) discloses a conventional liposome applying
hydrogenated naturally occurring phospholipids to
obtain a stable form of liposome. A fatty acid,
preferably oleic acid at above 10 w% but preferably
below 15 w%, yields the most stable form of liposome
capable of holding a drug within. Under these
conditions, lecithin at its optimal weight percentage
will form a lamellar liposome having oleic acid in the
middle. However, at higher weight percentages of oleic
acid, the phospholipids will form a micelle with oleic
acid in the core, not a liposome. As disclosed by
Wallach, Nakagama et al. applied cholesterol and
tocopherol to strengthen the physical stability of the
liposomal membrane, and applied negatively charged
materials to achieve a slow releasing liposomal
formulation within the body. After an intravenous
infusion of liposomes containing 10,000 U of urokinase,
a slow and sustained release of urokinase was observed
in rabbits.
Both Wallach's and Nakagama et al.'s compositions
are different from the compositions of the present
invention. For example, both Wallach and Nakagama et
al. have applied cholesterol, in combination with
tocopherol and oleic acid, to strengthen liposomal
membranes, and both have also applied a series of
charged phospholipids, but neither have directly
treated pharmaceutical agents such as peptides or drugs
with, for example, phospholipids or cholesterol,
although they have added surfactants.
In addition, in one embodiment of the present
invention, microparticles comprising the
pharmaceutically active agent urokinase (referred to
herein as uPA) may be made by using
glycerophosphorylcholine (referred to herein as GPC)
and a water soluble cholesterol in the presence of a
R'O 95/12385 . PCT/US94/12351
_12_
nonionic surfactant having an HLB value of above 15,
and the microparticles are suspended in micelle in a
fatty acid having a chain length of C14 or less
(referred to herein as MCT). A small amount of PC
and/or PS may be added together with another nonionic
surfactant ,(having an HLB value of less than 6). The
liposomal uPA of Honda arid Nakagama et al. is believed
to be absorbed~via alpha-glycerophosphate pathways
which are involved in intramembranous syntheses of
chylomicron, apoproteins, etc. and drained through the
lymphatics. However, in the present invention, the
uPA-containing microparticles in micelle (and not in
liposome), for example, are believed to be (and
preferably are) absorbed via the monoglyceride pathways
(as is MCT) and channeled into the portal system.
U.S. Patent No. 4,849,227 (Cho) disclosed a system
in which a pharmaceutically active peptide was ~~pinned"
into solid cholesterol granules in the presence of
sodium lauryl sulfate, coated with a solution
containing mono-, di-, or tri-glycerides and fatty
acids; coated with water soluble materials, e.g.
hydroxypropylcellulose, and enteriocoated. The
resultant dried powder was packed into a hard gel
capsule or made into a pressed tablet. The absorbed
cholesterol-bound insulin was believed to form
chylomicron in vivo. It was found to be bioavailable
and bioactive in some diabetics: i.e. an oral insulin
dosage between 0.33-0.74 U/kg (average 0.5U/Kg)
effectively lowered blood sugar and increased serum
insulin levels.
PCT Pat. Appl. PCT/GB91/00510 (Cho) discloses the
oral delivery of peptides by the integration of
peptides with specially selected, neutrally charged
phospholipids and apoproteins (e.g. apoprotein B48, AI,
AII, etc.) or those known precursors of in vivo
formation of such apoproteins (e. g. oleic acid, etc.).
WO 95112385 _ PCT/US94/12351
-13-
It is believed that membrane-integrating compounds are
associated with the biologically active materials and
integrated into forming the membrane system of
chylomicron. Chylomicron forms a remnant chylomicron
in the blood circulatory system, which is channeled
into the liver. Thus, a peptide (e. g. insulin) bound
with the membrane system of chylomicron may be
channeled into the liver. Such a system is absorbed
and forms part~of a chylomicron, and is distinguishable
from the disclosures of Wallach and Nakagama et al., in
that neither Wallach nor Nakagama et al. are directed
to formation of the membrane of remnant chylomicron.
The present invention, for use in oral insulin
formulations and other applications, is significantly
different from all the above-cited disclosures. For
example, in cholesterol - and the phospholipid-bound
insulin microparticles in micelle embodiment of this
invention after oral or TuD administration, the
composition is absorbed and predominantly channeled
into the portal system and then the liver as well as
systemic. circulation.
In the above-cited disclosures, various lipids
and/or surfactants are used to deliver (orally or
otherwise) peptides/drugs through mechanisms of known
or as yet unknown transmembranous absorptions. Such
mechanisms may involve, e.g. liposomes, lipospheres,
lipoprotein-microparticles, lipid vesicles, and others,
which are predominantly known to involve syntheses of
chylomicron, apolipoproteins, lipoproteins or others
within the absorptive membrane, and which are
ultimately drained through the lymphatic vessels and
thoracic duct. The overall absorption of such
peptides/drugs by applying the above described
formulations may be sporadic, erratic, unpredictable,
and lacking uniformity in terms of bioavailability.
This is expected from the characteristic physiological
wo 9sn23ss
PCTIU594112351
~1'~54~4
-14' . . ,
flow-kinetics of lymph fluids from the thoracic duct as
the lymph fluid outflow from'the thoracic duct is
sporadic and not a uniform steady flow.
More particularly, PCT Patent Application
PCT/GB91/00510 (Cho) discloses oral delivery systems
for peptides, such as insulin, by dissolving the
insulin into a hydrophilic solution, which contains a
surfactant having an HLB value of 14 or above, and a
lipophilic solution containing cholesterol:PC (at
usually 6-8: 1 ratio), apolipoproteins, 50 w/v% or more
of oleic acid to hopefully enhance an in vivo syntheses
of apoprotein, chylomicron, lipoproteins, etc. at the
intestinal membrane, involving the glycerophosphate
pathways. In the present invention, the water soluble-
phospholipid bound microparticles are suspended in MCT
micelle. However, the solutions of Cho
(PCT/GB91/00510) were microfluidized and made into a
microemulsion.
fiasco discloses formulations containing various
drugs in solid lipid microspheres. More particularly,
fiasco discloses a microemulsion prepared by contacting
a molten lipid (which may contain a drug) with a
mixture of water and surfactant heated to the lipid s
melting temperature, and dispersing the microemulsion
in water to create a lipid microsphere dispersion. It
is believed, based upon the disclosure of fiasco, that
such microspheres resemble a liposome described by
Fabre, H, et al. in J. Phys. Chem. 85: 3493, (1981).
fiasco also discloses lyophilization of the microsphere
dispersion. However, it is believed that any freeze-
drying or heating of an emulsion, microemulsion,
liposphere, liposome, lipid vesicle, micelle, or solid
emulsion (e. g. U.S. Patent No. 4,849,227 (Cho)) will
cause irreversible damage to the system and may
deteriorate the bioactivities of the pharmaceutically
active agents, especially peptides, glycoproteins, etc.
R'O 95112385 . PCT/US94/12351
'21 ~~'~~~ _15-
Gasco does not disclose any biological data after
applying the lipospheres containing
deoxycorticosterone, salbutamol, salmon calcitonin,
somatostatin, and erythropoietin. It is believed that
these compounds may be partially inactivated by heating
together with the fatty acids applied by Gasco.
In addition, there are no related known
disclosures relating to the embodiment of the present
invention wherein trans-umbilico-dermal delivery of the
compositions of this invention is employed. Other
formulations and methods for delivery of drugs or
peptides, although different than the present
invention, are summarized as follows:
Liu, J.C. in Internat. J. Pharm. 44: 197 (1988)
applied an iontophoresis of d.c. current of various
wave form to facilitate and regulate the transdermal
("TD") delivery of insulin in rats. U.S. Patent
Application Nos. 804661 and 899049, now U.S. Patent No.
5,023,252 (Hsieh) disclose anhydrides and esters of
macrocyclic lactone and ketones at 0.1-30 wt. % as a TD
enhancer for a drug (e. g. triamcinolone acetonide).
U.S. Patent No. 4,649,075 (Jose) discloses a foam
device which is a disk on a truncated inverted cone of
macroporus cellular polymer core containing insulin,
nonoxylnol-9, ocotoxynol, etc. and an outlayer
containing a microporous cellular polymer. Makino, Y.
et al. (Japan Pat. Appl. 84/182724) have used
pyroglutamates as a dermal penetrating enhancer for TD
delivery of indomethacin. PCT Publication No. WO
85/05036 (Weber, C.J. et al.) discloses the use of 33-
50% DMSO and 2.5% of HPMC gel as a penetrating enhancer
for TD delivery of insulin. M. Ferreira Mouta, Jr.
(Braz. Pedido PI BR 84/1369 A) discloses mixed insulin
with an oily excipient and incorporated with a plaster
for TD delivery of insulin. Nagai, T.J. in Controlled
Release 2:121 (1985) has incorporated triamcinolone
CA 02175494 1999-11-15
-16-
with~carbopol-934, a brand of carbomoer, and applied it
on an adhesive layer of HPC for buccal mucosal delivery
of insulin. German Pat. No. DE 3406497 (Franzky
et al.) discloses dissolved isosorbide dinitrate in a
5 mixture of polyethyleneglycol-glycerin partial ester
with oleic acid, glycerin partial ester with capric and
caprylic acids, isopropyl palmitate and water in the
presence of a surfactant having an HLB value of 8 and
cosurfactant having an HLB value below 8, and applied
10 isosorbide for use as a trans-dermal (TD) system.
Kazim, M. et al. in Surg. Forum 35: 64 (1984) has mixed
insulin with the penetration enhancers DMSO and n-
decylmethyl sulfoxide, and applied the mixture over the
skin of streptocin-induced diabetic rats, covered it
15 with a nonporous polyethylene patch, and observed
antihyperglycemic effects in rats.
The above and other cited references have not made
any disclosures of any compositions useful in
transdermal applications of compositions which are
20 similar to the compositions of the present invention.
More particularly, the dermal areas on which these
other TD formulations were applied are entirely
different from the embodiment of the present invention
which is specifically concerned with a trans-umbilico-
25 dermal application of compositions of the present
invention via falciform ligament and its anatomically
associated system.
In the early 1980s, the Belmac firm of Tampa,
Florida, developed a "navel drop" which consisted of
30 camphor which was dropped into the navel foci, was
absorbed through the falciform ligament and its related
system into the mesenteric and portal vasculatures,
induced a vasodilation and was supposed to have
improved hemorrhoidal conditions in humans. Camphor,
35 among other compounds, causes cutaneous vasodilation
(Bowman, W.C. & Rand, M.J. in Textbook of Pharmacoloay,
TRADE MARS
R'O 95112385 PCT/US94/12351
~~ _17_
2nd ed., p. 16.3 (1980)). Therefore, after dropping
the navel drop (camphor) into a human navel, its being
a cutaneous vasodilator, it is readily absorbed via the
falciform ligament and its surroundings. However, an
administration of any other TD forms of macromolecules
or drugs, unlike the pure campE~or, may not be readily
absorbed through the falciform ligament. Such a TD
formulation has to be modified specifically for the
trans-umbilico-dermal delivery system. The trans-
umbilico-dermal delivery system embodiment of the
present invention and the "navel drop" containing
camphor as its main component are thus entirely
different, as the present invention relates to
transdermal delivery formulations for pharmaceutically-
active agents (e.g. peptides or drugs) which may be
effectively administered via the falciform ligament.
The micelles of this invention, like compounds
such as glycerol and fatty acids having a chain length
of less than about C14, monoglycerides, diglycerides,
and the products of triglyceride hydrolysed by
pancreatic lipase (e. g. 2-monoglycerides) are believed
to be absorbed, via monoglyceride pathways, readily and
rapidly from the cellular membrane by a passive
diffusion mechanism, and are directed into the portal
system. The absorption of relatively large and
complexed systems, as discussed by Larsen, K. et al. in
Chem. Phys. Lipid, 12:321 (1980) or, e.g. an infinite
periodic minimal surface (IPMS) as discussed by
Longley, W. et al. in Nature 303:612 (1983) may be by a
mechanism grossly similar to those involving
pinocytosis or endocytosis. However, in such a
mechanism the absorbed lipid apparently does not
involve alpha-glycerophosphate pathways but rather the
emonoglyceride path and is thereby channeled into the
portal system. This is different from the known
mechanism of absorption of fatty acids having a chain
wo 9snasss PCT/US94/12351
-18- !
~,~~~ r~ 4g ~
length of C16 and above (referred to herein as LCT),
emulsions, liposomes, lipid vesicles, lipospheres, etc.
which are absorbed via the alpha-glycerophosphate
pathways at the membrane, are involved in syntheses of
chylomicron, membranes for chylomicron, lipoproteins,
apoproteins,and others at the cell membrane, and are
channeled through lymphatics into the thoracic duct.
LCT are primarily absorbed from the cell membrane by
pinocytoses or other as yet unknown mechanisms. An
involvement of Pyer~s patch at the small intestinal
membrane, for the absorption of IPMS, liquid-
crystalline phase of micelle, etc., is a plausible
hypothesis. (Larson et al.; Longley et al.).
Without wishing to be bound by any one theory, it
is believed that after the microparticles (containing a
pharmaceutically active agent) in micelle of this
invention are absorbed by the human body, they are
channeled into the portal system. The formulation may
contain one or more inhibitors for reticuloenthothelial
system (RES) activity. The invention is capable of
being passed through the absorptive columnar
enterocytes, the Pyer~s patch and others. The
pharmaceutically active agent may thus be channeled
into the portal system. When a fatty acid having a
chain length of C14 or less (referred to herein as MCT),
a lysophospholipid (referred to herein as lyso-PL), and
a fatty acid salt are added into the water, a lamellar
L-alpha (lamellar or liquid crystalline) phase of the
micelle is formed. At relatively high lipid
concentration of the micelle, in the presence of
phosphatidylcholine (PC), sphingomyelin,
phosphatidyiserine (PS), etc.,-the spherical micelle is
transformed into a rod shaped micelle. When the lipid
concentration is increased further, especially in the
presence of cardlollpin, phosphatidic acid (referred to
herein as PA), a hexagonal lipid cylinder (liquid
W O 95112385 PCT/US94/12351
,1 ,a .-
-19-
i ~ .
crystalline phase, or H1) is formed. It is possible to
formulate, e.g. by using PC, a lamellar liquid
crystalline phase with solvents other than water, such
as ethylene glycol, and properly secreted surfactants.
The spherical, rod-shaped, lamellar L-alpha or liquid
crystalline. phases may be obtained by simply altering
the concentrations and the types of lipids used, by
changing the temperature of solvents used, by selecting
appropriate phospholipids, (referred to herein
generally as PL), by changing the fluidity of protein-
bound lipids, etc. These various phases involving the
lipids-water (or other selected solvent) interactions,
are generally known as micelle. (Larsson, R. et al. J.
Colloid, Interface Sci. 72: 152, (1979); E1-NOkaly, M.
et al., J. Colloid Interface Sci. 84:228 (1981)).
A microemulsion is the reversed type of liquid
phase of an ordinary L1 phase micelle. For example,
water aggregates in a continuous hydrocarbon chain
medium and water lamellae are separated by lipid
bilayers (L2 phase) in aqueous systems of polar lipids
and triglyceride oil. In the presence of, for example,
lyso-phophatidylcholine (referred to herein as lyso-PC)
it becomes a microemulsion. Liposomes are formed when
water is added into the lamellar liquid-crystalline
phase at above its swelling limit by gentle stirring.
The lamellar liquid crystalline phase may consist of
concentric lipid bilayers alternating with water
layers. Sonicating the unilamellar aggregates under
certain conditions may yield lipid vesicles. By
further diluting the liposome, a so-called liposphere
may be formed. The pharmacokinetic properties of a
micelle, especially during its absorption from the
cellular membrane and the transporting systems
involved, are significantly different from that
observed after introducing a pharmaceutically active
agent within a liposome, microemulsion, lipid vesicle,
R'O 95/12385 _ PCT/US94/12351
-20-
liposphere, emulsion, or lipid suspension. (Ekwall,
P., Advances in Liquid Crystals, Vol. 1, Chapter 1,
Academic Press, N.Y. (1975)).
For example, in one embodiment of this invention,
urokinase (referred to herein as uPA) is employed as
the pharmaceutically active agent, the microparticles
were made with specially prepared, water soluble
cholesterol made in accordance with the method of
Proksch et al. in Clin. Chem. 24/11:1924-26 (1978)
to (i.e. polyoxyethanyl-cholesteryl adipate, containing
about 30% water soluble cholesterol and GPC, a water
soluble enzymatically hydrolysed PC, i.e. sn-3-
glycerophosphorylcholine, obtained after incuvating PC
with its specific hydrolysing enzyme, phospholipidase-
B, prepared by the method of Kates described in
Techniques in Lipidology, Elsevier, Amsterdam (1972).
The uPA in sodium phosphate buffer solution (pH 7.4)
was bound with GPC:GPS (4:2-1 Mol ratio), and the water
soluble cholesterol (4:2-1 Mol ratio of C:PC) iri the
presence of lyso-PC (i.e. sn-1-acyl-3-
glycerophosphorylcholine, a lipid soluble end product
of PC hydrolysed by phospholipidase-A2) and a nonionic
surfactant (polyoxy-40-stearate), and made into
microparticles in 15-20 v/v $ of the final volume of
MCT. The MCT contained another nonionic surfactant
having an HLB value of less than 6. The MCT and above-
described mixture were micronized to form uPA-
containing microparticles suspended in MCT micelle.
The overall bioavailability and bioactivity of the uPA-
3o microparticles in MCT micelle was excellent. In
addition, assaying for uPA from serum/plasma samples
and for uPA microparticles in MCT-micelle, in vitro,
using the ELISA method, was found to be easier when uPA
was bound to GPC/GPS-water soluble cholesterol, as
compared with when uPA was 'bridge-locked' with PC, PA
apoproteins cholesterol, etc., as disclosed for example
R'O 9511385 PCT/US94/12351
~ ~l?''~~~~
-21-
in PCT/GB91/00510 (Cho), and Chung, K.H., Chung, J.S. &
Cho, Y.W.: Presented at 13th Congress International
Soc. Thrombosis & Homeostasis, July 3, 1991, Utrecht.
discussed above. The stability of this embodiment of
the invention was good; however, it was further
stabilized by adding less than 5w/v% of LCT into the
MCT-micelle, and by adding a small quantity of PC and
PS, into the MCT solution.
In another embodiment of this invention, the
pharmaceutically active agent is quinine which is
contained within microparticles suspended in the MCT
micelle. After oral or TuD administration and
absorption, it.is targeted to erythrocytes and
hepatacytes hosting plasmodium malarial parasites which
may utilize the components therein (i.e. microparticles
containing quinine which are suspended in micelle to
repair the damaged membrane of erythrocytes and
hepatocytes. Also, microparticles containing
vincristin have been successfully targeted to
experimental IgM Immunocytoma cells in Wister rat and
introperitoneally inoculated P388 mouse leukemic cells.
In one particularly, preferred embodiment, water
soluble cholesterol is added as a sterol, to stabilize
the microparticles in MCT micelle. Optionally, an LCT
(i.e. having a chain length of C16 or higher, preferably
Clg such as 1; 9-octadecenoic) may be added to the MCT
micelle (at a concentration of 5w/v% or less of the
final MCT-micelle) to augment and stabilize the MCT-
micelle. After adding properly selected surfactants to
the LCT at or above the critical-micelle-concentration
(CMC) (but preferably at or below 5 w/v%), a second
micelle (i.e. LCT micelle) is formed. This LCT-micelle
is compatible with the MCT-micelle containing the
microparticles.
R'O 95112385 ~ - PCTIUS94/12351
z:
22
The objects and features of the present invention
will be apparent from the following detailed
description and the claims.
$~it~mary Of the Invontinn
The present invention relates to pharmaceutical
compositions comprising microparticles suspended in
micelle in at least one fatty acid having a chain
length of C14 or less. The microparticles comprise at
least one pharmaceutically-active agent, at least one
water soluble or miscible phospholipid, at least one
lipid soluble or miscible phospholipid, at least one
non-ionic surfactant having an HLB value of about 15 or
greater, at least one non-ionic surfactant having an
HLB value of about 6 or less, and at least one water
soluble or miscible sterol. In a particularly
preferred embodiment, the lipid soluble phospholipid is
an enzymatically hydrolyzed phospholipid lipid soluble
end product, i.e. a lysophospholipid. The
pharmaceutical composition may additionally comprise at
least one long chain fatty acid having a chain length
of C16 or greater, present in a concentration of no
greater than about 5 w/v$ based upon the total
composition.
The present invention also relates to a method of
preparing the above-descried pharmaceutical composition
comprising: (a) admixing at least one
pharmaceutically-active agent with at least one water
soluble or miscible phospholipid, at least one lipid
soluble or miscible phospholipid, at least one non-
ionic surfactant having an HLB value of about 15 or
greater, at least one non-ionic surfactant having an
HLB value of about 6 or less, and at least one water
soluble or miscible sterol and micronizing the
admixture to form microparticles; and (b) suspending
the microparticles in at least one fatty acid having a
WO 95/12385 PCTIUS94/12351
-23-
chain length of C14 or less to form microparticles in
micelle. The microparticles nn micelle may thereafter
optionally be admixed with at least one long chain
fatty acid having a chain length of Cifi or greater,
which is present in a concentration of no greater than
about 5 w/v% based upon the total composition.
The present invention also relates to a method of
irans-umbilico-dermal administration of a
pharmaceutical composition to a patient, which
comprises contacting the dermal area of a patients'
navel with the above-described pharmaceutical
compositions. The present invention also relates to
the use of such compositions for treatment of diabetes,
administration of antibiotic therapy, treatment of
hypertension, cancer or chemotherapy treatment,
administration of hormonal therapy, administration of
antiparasitic therapy, and for targeting delivery of
the pharmaceutical composition to a specific organ.
Brief Description of the Draw~nos
Fig. 1 illustrates blood glucose levels obtained
after oral administration of glyburide plus insulin in
accordance with this invention compared to levels
obtained after oral administration of glyburide alone
in glyburide-resisting NIDDM patients.
Fig. 2 illustrates serum glyburide and serum
insulin concentrations obtained after oral
administration of glyburide plus insulin in accordance
with this invention compared to levels obtained after
oral administration glyburide alone in accordance with
this invention in glyburide-resisting NIDDM patients.
peta~~ed Description of the Invention
The pharmaceutical composition of this invention
contains microparticles suspended in micelle in at
least one fatty acid having a chain length of C14 or
W095/12385 _ _ ' PCTIU594112351
-24-' ~'. . .
less (referred to herein as MCT). The microparticles
contain one or more pharmaceutically-active agents
which may be peptides, drugs or nutritional food
products which have enhanced bioavailability and
activity after the oral, rectal, trans-umbilico-dermal,
buccal, sublingual, intranasal, intrapulmonic, or
ocular administration of such a composition. Such
formulations may be applied for targeting the
composition as a slow, controlled-release formulation
for special organs or tissues, and may be given orally,
parenterally, intrathecally (for delivering into the
brain and the spinal cord areas), transdermally, or by
other means. The pH for the pharmaceutically-active
agents may be adjusted to the optimal pH, in vitro, for
the pharmaceutical agent or agents employed. As used
in this specification and in the appended claims,
"micelle°' refers to the high degree of association of
microparticles in solution typically observed, for
example, with respect to molecules or ions of many
surfactants, as described for example in Vol. 4 of the
Encyclopedia of Chemical Technology (R. Kirk and D.
Othmer, eds. (1954)), pp. 939-40. Thus the
microparticles in the present invention are highly
associated when suspended in the C14 or less fatty acid.
As used in this specification and the appended claims,
the term "fatty acid" means monobasic organic acids of
chain length C1 or greater, as set forth, for example,
at page 281 of the Von Nostrand Chemist s Dictionary
(1953). In this specification and the appended claims,
"fatty acid" may be further modified by specifying a
specific chain length.
The microparticles are suspended in micelle in at
least one fatty acid having a chain length of C14 or
less, preferably C12 or less. Such fatty acids include
formic, propionic, butyric,, valeric, caproic, caprylic,
capric, lauric~and myristic acid and mixtures thereof.
wosmzsss . rcr~s9an~si
~!~ l~~ -25- _;
In preparing the microparticles of this invention
which are then suspended in MCT micelle, the
pharmaceutically-active agent is made relatively
stable, and is noncovalently and reversibly bound with
at least one water soluble or miscible phospholipid,
without degradation of the pharmaceutical agent.
While not wishing to be bound by any one theory,
it is believed that noncovalent bonds between the agent
(e.g. a peptide) and the phospholipid which may
1o stabilize peptide structure are ionic bonds, hydrogen
bonds, hydrophobic interactions, and the Van der Waals
interaction. A lipid such as a phospholipid may
strongly bind with a peptide at various radical groups
of the peptide, such as at carboxyl, sulfonyl,
hydroxyl, amino, and ammonial radicals, and lipids may
form esters or ethers with the peptide. This type of
binding should be avoided. Bile salts, for example,
are strongly charged and may change the properties of a
peptide, and thus should not be employed as a
surfactant in this invention.
The pharmaceutically-active agents which may be
employed in the present invention include, but are not
limited to: (1) peptides such as insulin, growth
hormones, interferon, calcitonins, urokinase,
coagulation Factor-VIII, coagulation Factor IX,
erythropoietin; (2) compounds having poor
bioavailability and/or compounds for targeted delivery
to specific organs or systems, such as nafcillin,
vincristin, cephazoline, doxorubicin, quinine,
chloroquine, primaquine, d-alpha-tocopherol (which is
also an antioxidant), and gentamicin; (3) compounds
which, after absorption, are predominantly bound to
plasma proteins and/or rapidly biotransformed at the
liver, thereby exhibiting poor bioactivity, such as
glyburide, indomethacin, oxyphenbutazone,
chlorothiazle, propranolol, cyclophosphamide; and (4)
R'O 95112385 PCT/US94/12351
._
26
those neuropharmacologics which mimic sustained
intravenous infusion of compounds, preferably those
capable of crossing the blood-brain-barrier membrane,
such as physostigmine, fluoxetine, and feldene.
As will be apparent to those skilled in the art, the
choice of agent or agents employed is dependent upon
the condition, disease or illness being treated, or the
therapy to be employed. In a particular preferred
embodiment, the peptide is insulin, and the composition
is employed for the treatment of diabetes. In another
particularly preferred embodiment, the agent is
vincristin, and the composition is employed in cancer
treatment.
As used in this specification and the appended
claims, the term "water soluble or miscible
phopholipid" refers to phospholipids (referred to
herein generally as PL) and phospholipid derivatives
which are water soluble or miscible, either alone or in
the presence of a suitable nonionic surfactant or
surfactants, or a suitable hydrolyzing enzyme. For
example, phospholipids which are capable of water
solubility or miscibility in the presence of suitable
surfactants and/or hydrolyzing enzymes include
diacylglycerols, phosphatidylcholines (PC),
phosphotidylethanolamines (PE) (which are
zwitterionic),~phosphatidylserines (PS),
phosphatidylglycerols (PG), phosphatidylinositol (PI),
diphosphatidyl glycerol (OPG), and phosphatidic acid
(PA). Other water soluble or miscible phospholipids
which may be employed in the present invention include,
but are not limited to, glycerophospholipids such as
glycerophosphates (GP) (e.g, sn-1- and sn-3
glycerophosphate), glycerophosphorylcholines (GPC),
glycerophosphorylethanolamines (GPE) (e.g. sn-3-
glycerophosphorylethanolamine), cholines,
phosphorylcholines, phosphorylethanolamines,
CA 02175494 1999-11-15
-27-
ethanolamines, glycerophosphorylserines (GPS) (e.g. sn-
3-glycerophosphorylserine), glycerophosphorylglycerols
(GPG) (e.g. sn-3-glycerophosphorylglycerol), and
mixtures thereof.
5 Water soluble or miscible phospholipid derivatives
suitable for use include water soluble or miscible
enzymatic hydrolysis end products of phospholipids. As
used in this specification and the appended claims,
"water soluble or miscible enzymatic hydrolysis end
10 products of phospholipids" refers to water soluble or
miscible end products obtained after incubating a
specific phospholipid with its specific hydrolyzing
enzyme to obtain such an end product. For example,
phosphatidylcholine (PC) may be enzymatically
15 hydrolyzed by incubating with the enzyme phospholipase-
B to yield water soluble glycerophosphorylcholine
(GPC). A particularly preferred embodiment of GPC is
sn-3-glycerophosphorylcholine. Similarly,
phosphorylglycerol (PG) may be enzymatically hydrolyzed
20 by incubating with the enzyme phospholipase-B to yield
water soluble glycerophosphoryglycerol (referred to
herein as GPG). A particularly preferred embodiment of
GPG is sn-3-glycerophosphorylglycerol. Such enzymatic
hydrolysis end products may be prepared by the method
25 disclosed in M. Kates, Techniques in Lipidology
(Elsevier, Amsterdam 1972), and are well known to those
skilled in the art.
Alternatively, water soluble GPC may be prepared
30 from egg yolk lecithin by applying selective alcoholysis
with methanolic tetrabutylammonium hydroxide solution
according to a modified version of the method of H.
Brockerhoff and M. Yurkowski in Canadian J. Biochem.
43:1777 (1965)
35
WO 95112385 PCTlUS94/12351
21°~549~ 2$
As used in this specification and the appended
claims, the term "lipid soluble or miscible
phospholipid" refers to phospholipids and phospholipid
derivatives which are lipid soluble or miscible, either
alone or in the presence of a suitable surfactant or
surfactants,,or a suitable hydrolyzing enzyme. In a
particularly preferred embodiment, the lipid soluble or
miscible phospholipid derivatives suitable for use are
lipid soluble or miscible enzymatic hydrolysis end
products of phospholipids. These end products are
referred to herein as lysophospholipids, or lyso-PL.
As used in this specification and the appended claims,
"lipid soluble or miscible enzymatic hydrolysis end
products of phospholipids" refers to lipid soluble or
miscible end products obtained after incubating a
specific phospholipid with its specific hydrolyzing
enzyme to obtain such an end product. For example,-
phosphatidylcholine (PC) may be enzymatically
hydrolyzed by incubating with the enzyme
phospholipidase-A2 to yield lipid soluble lyso-PC (i.e.
sn-1-acyl-3-glycerophosphorylcholine). Such enzymatic
hydrolysis end_products may be prepared by the method
of Kates, referenced above and are well known to those
skilled in the art. Lipid soluble enzymatic hydrolysis
end products particularly preferred for use as in this
invention are exemplified by those set forth in the
following table, together with the corresponding base
phospholipid (PL) and enzyme employed to product the
enzymatic hydrolysis end product or lyso-PL:
R'O 95112385 . PCT/US94/12351
zl~~'4r~ -29-
GI ' s .'.
T' F~ ylr. ~' ~ 7
j
Base Phoapholipid Enzyme Lipid Soluble
(pL) enzymatically hydrolyzed
end product (referred
to
generically as lyso-PL)
PhoaphatidylcholinePhoapholipase-A2 an-1-acyl-3-glycerophos-
(pC) hor lcholine (1 so-PC)
Phos hali ase-C sn-1,2-disc 1 lycerol
Phospholipase-D sn-1,2-diacyl-3-
1 cero hoa hate
PhoaphatidylglycerolPhoepholipase-A2 an-1-acyl-3-glycerylphca-
(pG) phorylglycerol (lyso-PG)
Phos holi ase-C sn-1,2-disc 1 1 cerol
Phospholipase-D an-1,2-
diac 1 1 cerol hos hate
Phoaphatidic Acid Phospholipase-A2 an-1-acyl-3-
(pA) glycero hoaphate (1 so-PA)
Phosphatase sn-1,2-disc lglycerol
Phoaphatidylethanol-Phospholipidase- an-1-acyl-3-
amine (PE) A2 glycerophoaphoryl
ethanolamine 1 so-PE
Phos holi ase-C an-1,2-disc 1 1 cerol
Phospholipase-D sn-1,2-diacyl-3-
1 cero hos hate
Phoaphatidylserine Phospholipase-A2 sn-1-acyl-3-
(pg) glyceraphosphorylserine
(lyso-PS)
Phoapholipase-D an-1,2-diacyl-3-
glycerophoaphate
Other lipid soluble or miscible phospholipid enzymatic
hydrolysis end products suitable for use include, for
example: 1-Myristoyl-sn-glycero-3-phosphocholine; 1-
Myristoyl-sn-glycero-3-phosphoethanolamine; 1-
Myristoyl-sn-glycero-3-phospho-(N,N-dimethyl)-
ethanolamine; 1-Palmitoyl-sn-glycero-3-phosphocholine
(or ethanolamine); 1-Palmitoyl-rac-glycero-3-
phosphocholine; 1-Palmiltoyl-sn-glycero-3-phospho-(N, N-
dimethyl)-ethanolamine; 1-Stearoyl-sn-glycero-3-
phosphocholine, and mixtures thereof.
More than one water soluble or miscible
phospholipid may be used in the preparation of the
microparticles.. For example, in one preferred
WO 95/12385 PCT/US94I12351
21'~~494. 3°
embodiment, the pharmaceutically active agent may be
bound to, for example, GPC and/or GPS by being mixed
and incubated with, e.g., lyso-PC, while gently stirred
at 25°C in a water bath.
The microparticles may also additionally comprise
at least one lipid substrate compound selected from the
group consisting of phosphatic acid, phosphatidylcho-
line, phosphotidylethanolamine, and phosphatidylserine
and phosphatidylglycerol, and mixtures thereof. Such
lipid substrates may aid in stabilizing the MCT micelle
composition of'this invention.
Other lipid soluble materials which may be
employed in conjunction with the lysophospholipids
include 1-Oleyl-2-acetyl-sn-glycerol, 1,2-Dioctanoyl-
sn-glycerol, 1,2-Didecanoyl-sn-glycerol, etc.; some of
the 1,2-Diacyl-phospholipids may include 1,2-Dioleoyl-
sn-glycero-3-phosphocholine, 1,2-Dimyristoyl-sn-
glycero-3-phosphocholine, 1,2-dimyristoyl-rac-glycero-
3-phosphocholine, 1,2-Dimyristoyl-sn-glycero-
phosphoethanolamine, 1,2-Dimyristoyl-sn-glycero-3-
phosphatidic acid (Na), 1,2-Dipalmitoyl-sn-glycero-3-
phosphocholine, 1,2-Dipalmitoyl-sn-glycero-3-
phosphoethanolamine, 1,2-Distearoyl-sn-glycero-3-
phosphatidic acid (Na), and mixtures thereof.
At least one water soluble or miscible sterol is
also present and is incorporated into of the
phospholipid while maintaining the structure of the
phospholipid and of the surfactant at an optimal
concentration to increase its adherence to absorptive
cells and to supplement the surfactant activity in
vivo. The sterols for use preferably include
cholesterol, cholesterol esters, cholesteryl-17-
bromohepta-decanoate, cholesteryl octonoate,
cholesteryl oleate, cholesteryl palmitate, cholesteryl
sulfate, cholesterol monohydrate, and mixtures thereof.
Such sterols may be made into water soluble form, e.g.
VVO 95112385 PCT/US94/12351
-31-
polyoxyethanyl-cholestryl adipate, which has been
solubilized as an L-alpha-phase of a lipid-water
system; or at least made into a water miscible sterol
by utilizing various surfactants. This invention
employs an application of the water soluble or miscible
sterol, wherein it is used in conjunction together with
of one or more enzymatically hydrolyzed and water
soluble phospholipids such as GPC or GPS, and
enzymatically hydrolysed end products of lipid soluble
materials such as lyso-PC.
The pharmaceutically-active agent (e.g. insulin or
glyburide), is admixed with at least one non-ionic
hydrophilic surfactant having a HLB
(hydrophile/lipophile balance) value of 15 or greater,
preferably above16, and at least one nonionic
lipophilic surfactant having an HLB value of 6 or
below, preferably 5 or below, with each dissolved in a
proper solvent. If necessary, the pH is adjusted, and
transport enhancers and/or protease inhibitors are
added.
The surfactants which may be employed in this
invention are preferably non-ionic surfactants, which
are well known to those skilled in the art.
Surfactants having HLB value of about 6 or less
include, but are not limited to substituted sorbitan
compounds, substituted glyceryl compounds, and
substituted polyoxyethylene compounds having from 1-100
oxyethylene moieties, preferably including sorbitan-
monocaprylate, sorbitan-monopalmitate, sorbitan-
monostearate, sorbitan-sesquistearate, sorbitan-
trioleate, sorbitan-monooleate, sorbitan-sesquioleate,
sorbitan dioleate, glyceryl-monosterate, glyceryl-
monoleate, glycerol-dioleate, decaglyceryl-
monostearate, decaglyceryl-pentastearate, decaglyceryl-
monolinolate, decaglyceryl-monolaurate, and
decaglyceryl-monomyristate.
CA 02175494 1999-11-15
-32-
Surfactants suitable for use having an HLB value
of 15 or greater include polyoxyethylenes and their
derivatives having from 1-100 oxygen moieties, such as
polyoxyethylene-lauryl ether, polyoxyethylene-
5 hydrogenated castor oil, polyoxyethylene-sorbitan
monooleate, polyoxyethylene-monostearate, and
polyoxyethylene-lauryl ether. The surfactants should
be carefully selected to avoid suppression of the
bioactivities of the pharmaceutically-active agents
10 employed. It will be understood that the applicable
surfactants are not to be limited to those named above
but may include other surfactants, including
emulsifiers.
In one preferred embodiment, the pharmaceutically
15 active agent Factor-VIII is combined with 4-1:1 Mol
ratio concentrations of GPC and GPS prepared as
disclosed by M. Kates. In the presence of a water
soluble cholesterol (polyethoxyethanyl-cholesteryl-
adipate prepared by the method of Proksch & Bondeman),
20 lyso PC at less than 0.005 mMol, aprotinin, and a
surfactant having an HLB value of above 15, such as
polyoxy 40-stearate in phosphate buffer. This solution
is added and mixed into MCT solution having an HLB
value less than 6 (e.g. glyceromonooleate), and
25 micronized at room temperature by using a modified
Nanmizer (the Freund Industrial Co., Tokyo) or a
* Microfluidizer (the Microfluidics Co., Newton, Mass.).
Just prior to administration of the above-
described composition, about 5 w/v% or less, preferably
30 less than about 4.5 w/v% (of the final product) of a
solution containing LCT, a nonionic surfactant having
an HLB value less than 6 and an antioxidant, may be
added to the composition and micronized at room
temperature, which may further stabilize the MCT-
35 micelle. Occasionally, a small amount of PC: PA (about
a 2-4:1 Mol ratio) may be included into the MCT so as
TRADE MARK
R'O 95/12385 _ PCflUS94/12351
-33-
to further stabilize the MCT-micelle. The
microparticles mixed with MCT (and optionally LCT)
water, oil, and the lamellar L-alpha-phase of micelle
may exist in equilibrium. (Rydhag. L. et al., J. Am.
Oil Chem. Soc. 58:830 (1981)).
The long chain fatty acids (LCT) in which the
microparticles suspended in MCT micelle may be further
admixed or suspended has a chain length of C16 or
greater. In one preferred embodiment, the LCT has a
chain length of C1$ or greater and at least one
unsaturated bond. In a particularly preferred
embodiment, such acids include 4- or 9- tetradecenoic,
9-hexadecanoic, 6-,9-, or 11-octadenoic acid, 9-, or
12-octadecadienoic, 9-, 12-, 15-, 11-, or 13-
octadecatrienoic, 9-, 11-, 13-, or 15-
octadecatetraenoic, 9-eicosenioic, 5-, 8-, 11- or 14-
eicosatetraenoic, 13-docosenoic, or 15-tetracosenoic
acid or combinations thereof. The long chain fatty
acid may also contain 20-50 v/v% of glycero-monooleate,
-dioleate, and/or -trioleate. By adding up to 5 w/v%
of the LCT to microparticles suspended in MCT micelle,
the microparticles suspended in MCT micelle may be
further stabilized. In one optional particularly
preferred embodiment, the LCT and additional nonionic
surfactant having an HLB value of 6 or below (as
previously described) may be added to the
microparticles suspended in MCT micelle.
The pharmokinetic behavior of pharmaceutical
compositions of this invention wherein 5 w/v% or less
LCT is added to the microparticles in MCT micelle
differs significantly from products containing say
greater than 10 w/v% LCT (e.g. oleic acid). At the
latter LCT concentrations, the pharmaceutically active
agent would be~in liposome or liquid sphere form, not
in micelle in accordance with this invention.
Accordingly, a composition containing greater than 10
WO 95/12385 PCT/US94/12351
-34-
,. ;, :,
w/v% LCT requires the active phamaceutical agent
contained therein to be absorbed via pinocytosis, etc.
and/or forming chylomicron, etc., which involves alpha-
glycerophosphate pathways, channeling through the
lymphatic system, and drained through the thoracic duct
in a sporadic, non-uniform way. When the optional LCT
concentration is 5 w/v% or less, as in one embodiment
of this invention, the MCT micelle is stabilized
without effecting the pharmokinetic, absorptive
l0 behavior of the MCT micelle and its associated
pharmaceutically active agent. Additionally, a small
amount of phospholipids and a nonionic, lipophilic
surfactant having an HLB value of 6 or less may be
added (together with the LCT) to the microparticles in
MCT micelle, to further stabilize the composition.
This invention also relates to a method of trans-
umbilico-dermal (TuD) administration of the
pharmaceutical composition of this invention to a
patient. The pharmaceutical composition is applied on
the skin area of the human navel, the falciform
ligament (paraumbilical veins) and its related system.
This pharmaceutical TuD delivery system may be applied,
for example, in the following settings: (1) for
targeting a cancer chemotherapeutic, e.g. doxorubicin,
into the liver, uterus, ovary, lung, stomach, rectum,
colon, etc.; (2) for delivering an antimalarial drug,
e.g. quinine, into plasmodium parasite-containing red
cells and hepatocytes; and (3) for administering a
cholinesterase inhibitor, e.g. physostigmine, through
the blood-brain barrier into CNS systems and improving
the cognitive functions of patients suffering from the
Alzheimer~s Disease, etc. An enhancer for the trans-
umbilico-dermal adsorption of such TuD formulations,
may be added. These may include, but are not limited
to, dimethyl formamide, propylene glycol, diethyl-m-
toluane, salicylate, and other adsorption enhancers, at
WO 95112385 PCT/US94112351
-35- _ .
concentrations well known to those skilled in the art.
In accordance with this invention, when a
pharmaceutically active agent residing in
microparticles suspended in micelle was administered
from the umbilical foci and channeled into the
mesenteric circulatory system and portal system, thus
directing the microparticles into the liver, the
overall pharmacological actions of the microparticles
was found to be similar to that of the results of slow,
intravenous infusion of the same pharmaceutically
active agent. Thus, this TuD administration of, e.g.
physostigmine, was found to have induced grossly
similar activities as compared with results obtained
after its intravenous injection. This is useful, for
example, in improving the cognitive functions of
patients suffering from Alzheimer's Disease. In
addition, insulin delivered via the TuD system was
found to cause increased serum insulin and decreased
blood sugar in diabetic patients, grossly similar to
the responses observed after slow intravenous infusion
of insulin. The TuD embodiment of this invention
includes applying compositions of this invention
dropwise onto the navel, patched over the navel, or
made into a "cream-type" formulation and spread over
the navel of human patients.
For the trans-umbilico-dermal ("TuD") delivery of
a pharmaceutically-active agent such as a peptide (e. g.
insulin) or of a drug (e.g. glyburide), the
compositions of the present invention should be
absorbed through the thin layer of non-fatty scar
tissue; and once the formulations are absorbed into the
mesenterics, the macrophageal systems and their
activities have to be retarded. It has been found that
a trans-umbilico-dermal administration of insulin in
accordance with the present invention was as effective
WO 95112385 PCTIUS94112351
6
.," , .
as that of a parenterally injected regular insulin in
diabetics. Furthermore, in accordance with this
invention, insulin may be dissolved in, e.g., ethanol,
in the presence of a group of enhancers for transdermal
penetration, e.g, hydrophilic/lipophilic surfactants,
propyleneglycol, dimethylformamide, diethyl-m-
toluamide, salicylates, etc., and made into stable
microparticles with a group of water soluble
glycerophospholipids in the presence of an optimal
concentration of tris galactoside-terminated-
cholesterol and lyso-PC in MCT.
Inhibitors for the macrophageal and for the
protease activities may also be added into the micro-
particle compositions. More particularly, inhibitors
for the macrophargeal system (e. g.
mucopolysaccharolproteins or mucopolysaccharolipids,
nonulosaminic acid, sialic acid) and protease
inhibitors (e.g. aprotinin) may also be added to the
microparticles.
The invented compositions, which include bound
bioactive agents (wherein the efficacy of such agents
is known to be activated by their intrahepatic
biotransformations) may be targeted for specific organs
such as the liver. The bioactivity of such compounds
can be enhanced while the systemic, toxic and side
effects of the compounds are reduced (e. g. phenacetin
is biotransformed into acetoaminophen).
The microparticles may also additionally comprise
at least one antioxidant compound. In one preferred
embodiment, the antioxidant employed may be d-alpha-
tocopherol.
In a preferred embodiment, the composition of this
invention is capable of slow, controlled release and of
being targeted at high dosage to the liver or other
organs. The above-mentioned inhibitors of macrophageal
activities, for example, sialic acid, may be replaced
WO 95112385 PCT/US94/12351
-37-
with, for example, one or more activator compounds. In
a preferred embodiment, substituted cholesterols such
as triantennary galactose-terminated cholesterols, most
preferably N-(tris-beta-D-galactopyranosyloxymethyl-
methyl)-N-(4-5-cholesten-3-beta-oxyloxy-
succinyl)glycinamide, or an ultramicronized
polyvinylpyrrolidone such as polyvinyl alcohol, or
similar compounds may be employed as activators.
In another preferred embodiment, by simply
eliminating the inhibitors for macrophageal activity
from the composition, it is believed that the
pharmaceutically-active agent in microparticle
suspended in micelle will be carried into the portal
veins and will.be channeled predominately to the liver.
The microparticles are prepared by micronizing the
above-described admixture of pharmaceutically-active
agent phospholipids, surfactants and sterol. As used
in this specification and the appended claims, the term
"micronized" refers to the method of reducing solid or
liquid particles in size by subjecting them to shear
forces, using techniques, procedures and equipment well
known to those skilled in the art. The microparticle
sizes of the composition of this invention preferably
have an average diameter in the range of 0.01-0.15 dam.
For example, when the composition comprises urokinase
(uPA) as the pharmaceutically active agent in MCT
micelle, the microparticle size is typically between
30-9o nm (within an average less than 60 nm); when the
agent is insulin, it is typically 0.01-0.07 ~m (with an
average in the range of 36 nm).
The micelle may also be converted into a dried
powder by spray coating the solution over a group of
inert chemicals, e.g. carboxymethylcellulose, alginate,
etc. The powder may then be packed into a hard gelatin
capsule or pressed into a tablet form. As used in this
specification and the appended claims, the term "inert
W095/12385 _ PCTIUS94/12351
3
<.
chemicals~~ refers to chemicals or compounds which are
not usually absorbed from the gastrointestinal system
after its oral intake, but instead are eliminated as
feces. Accordingly, such inert chemicals lack
appreciable systemic effect after intake.
The invention is exemplified by, but not limited
to, the following examples.
_ExamW p i
An oral insulin formulation having an enhanced
bioavailability and activity, and which mimics the
properties of endogenously secreted insulin, which is
primarily channeled into the liver, has been made and
one of the representative formulations is summarized as
follows:
To make a final volume of about 300 ml, a
sufficient quantity of bovine insulin (about 55 mg,
provided that one mg of such insulin powder/crystalline
has an activity of about 20 IU) to yield about 16 IU
per 5 ml of the final product or per 125 mg of the
formulation contained in microcapsules, was dissolved
in 95% ethanol (final volume made up to 75 ml)
containing about 2,200 KIU of aprotinin and adjusted to
about pH 2.8 by adding a saturated citric acid
solution. To 25 ml of 95% ethanol, about 0.85-12.5,
say 10.3 gm of glycerophosphorylcholine (GPC), about
4.1-6.3, say 5.2 gm of glycerophosphorylserine (GPS),
12.8-16.5, say 14.3 gm of water soluble cholesterol,
about 750-918, say 850 mg of lyso-PC, and about 2.2-
2.8, say 2.5 gm of polyoxy-40-stearate were added, and
(in order of the above listing) gently and slowly
dissolved at about 35-40°C in a water bath. To about
150 ml of MCT, about 4.6-6.8 say 5.5 gm of
glycerolmonooleate was added and dissolved, at about
35-40°C in a water bath. These two solutions were
gently mixed, homogenized, and the volume was made up
to about 280 ml by adding MCT, and micronized by using
WO 95/12385 . PCT/US94/12351
a .
1 .~r~~r . . .
-39-
either the Nanomizer or Microfluidizer (of the
Microfluidics Co. of Newton, Mass.) at room
temperature. The yield MCT-micelle containing insulin
in the micropaxticles was kept in a dark, brown glass
container and stored in a dark cool place at a
temperature between 2-8°C, but not permitted to freeze.
To about 3.5-5.0, say 4.7 w/v% of the final volume
of product, glyceromonooleate at about 2-6, say 4 v/v%
of the final volume of oleic acid applied, and about
1.0-2.5, say 1.8 gm d-alpha-tocopherol were added,
mixed, homogenized and passed 2-4 times through the
Microfluidizer at a shear force of 10,000 psi. A
proper quantity of antimicrobials, such as about 1.5 gm
sodium benzoate and about 1.5-3.8, say 2.0 mg of
nonulosaminic acid may be added into the above oleic
acid solution. Just prior to its administration to
human subjects, the microparticles suspended in MCT-
solution micelle and the oleic acid (i.e. LCT) solution
may be mixed and made up to 300 ml with additional MCT.
Each 5 ml of the final product may contain about 14-20,
say 16 IU of bovine insulin.
Alternatively, the above oleic acid solution may
be slowly homogenized in the MCT solution and after the
final volume is made up to 300 ml with additional MCT,
micronized for 5-10 min in cold by using a Nanomizer
(or passed through the Microfluidizer for 4-6 passes)
at room temperature.
Example lA
The final product of Example 1 may be spray-coated
over inert materials. Such inert materials include,
for example, calcium-carboxymethylcellulose (CMC-Ca),
hydroxypropyl cellulose (HPC) gelatin, etc. The dried
product may be~packed into a hard gelatin capsule or
made into a pressed tablet. A Spir-A-Flow (Mini Model)
CA 02175494 1999-11-15
-40-
of Fruend Industrial Co. of Tokyo may be applied. The
Spir-A-Flow is an improved fluidizer-coater.
In order to further preserve the chemical and
pharmacological activities as well as the stability of
5 the final product, it was made into microcapsules
(having a mean.diameter of about 0.5-1.5 say 0.75 mm0)
as follows:
The final product was spray coated with~COCONADE
(a commercial product of coconut oil of Kao Soap Co.,
l0 Tokyo) and gelatin in its liquid form. Both COCONADE
and gelatin, in a beaker in water bath, were heated at
40-70°C, and 50-90°C, respectively. The cool, final
product solution and two heated coating solutions were
sprayed at a rate of 15-20 ml/min for the product, 10-
15 16 ml/min for COCONADE, and 25-40 ml/min for the
gelatin solution, through the triple nozzles of the
* Spherex TRN (a product of Freund Industrial Co., Tokyo)
into a slowly rotating (with respect to its
longitudinal axis) round glass chamber-column of a
20 length of about 1.5 m and having a diameter of 20 cm at
the descending.part of its U-shaped tube.
Briefly, the two U-shaped tubes are connected in
such manner as to make a pressed S-shaped tube: i.e.
the first part of the descending part of U-tube, having
25 a diameter of about 20 cm and length of about 1.5 M is
attached (and funneled) to the ascending part of a
length about 2 M long, having a diameter of about 12
cm, which is further attached to the descending part of
the upside down U-tube having a length of about 1 M and
30 a diameter of about 12 CM. The outflow opening of the
upside down U-tube was attached to the collecting
sheave, collecting the microcapsules (less than 0.3 mm
in diameter) and cold vegetable oil was pumped into the
U-tube, and recirculated through the U-tube, starting
35 from the top of larger descending part of U-tube with
the input opening for the flowing vegetable oil, and
TRADE MARK
R'O 95/12385 _ _ _.. _ PCT/US94/12351
~1~~~ -41_
r/ 9g
was directed to the narrow, ascending part of the U-
tube, connected to another descending part of the
narrow U-tube. Another extremely cold vegetable oil at
temperatures of about 0-(-5)°C was circulated around
the pressed S-shaped tube.
As the microparticles in micelle and heated
droplets of the COCONADE and the gelatin solutions
impacted the cold oil in the rotating glass chamber-
column, microcapsules were formed containing the
microparticles at the middle, coated by the COCONADE,
and the outermost coating shielded by the hardened
gelatin, with sizes ranging between 0.5-1.5 mm. The
microcapsules were dried (at room temperature) and
packed into hard gelatinous capsules (i.e. each 125 mg
capsule to contain about 16 IU of bovine insulin). The
insulin within the microcapsules in the hard gelatinous
capsules was found stable for the six months of study
period.
Example 2
An glyburide-containing composition of the present
invention, useful as an oral anti-hyperglycemic, may be
wo 9snz3ss
PCT/US94/12351
21'5494
-42-
made and representative formulations are summarized as
follows: .
Quantity (per 400
M1)
Chemicals Bread Preferred
P
t
ar
-I 0.06-2.0 2.0
Glyburide
Mg/Capsule Mg/Capsule
Cholesterol 3.9-15.6 Gm 7.8 Gm
GPC 7.0-28.0 Gm 14.0 Gm
Lyso-PC 1.4-13.8 Mg 1.6 Mg
Ethanol 40-250 Gm
65 Gm
(95% in water)
Polyoxyethylene 40 0.05-20% + 5 $ +
stearate
+(w/V% of the Part I
solution)
Part-II
MCT oil 350-450 M1 400 M1
Make up to the final
volume of
Nonulosaminic acid 0.005-2.0 Mg 0.05 Mg
Sorbitan trioleate 5-30%++ 25%++
++(w/v% of the Part II solution)
Part-III
oleic acid 0.5-5 w/v% 4.5 w/v%
of Part-I/II
Glycerolmonooleate 0.5-15% v/v% 4.0 v/v%
of Oleate
d-alpha-tocopherol 0.5-2
5 Gm
. 1.2 Gm
(above quantity is per 400 M1 of the final composition)
Glyburide powder i s micronized with Jet Mill (made
a
by the Fruend Industria l Co. of Tokyo) di
and
, ssolved in
ethanol in the presence of polyoxyethylene- 4o-stearate
at
SLIBS1'ITi)1'E SHfEf (RULE 26)
VVO 951ll2385 PGT/US94/12351
-43-
room temperature, a water soluble cholesterol, and GPC.
Lysophosphatidylcholine (lyso-PCj is dissolved in MCT in
the presence of sorbitan trioleate and nonulosaminic
acid. Both solutions are slowly mixed and passed through
the nanomizer at a shear force of above 10,000 psi and
cooled. To the resultant solution, 5 w/v% or less of an
LCT (oleic acid) containing glycerolmonooleate and d-
alpha-tocopherol are added, and re-micronized at above
10,000 psi with cooling at four to five passes. The
final volume of the resultant solution is made up to 400
ml with MCT, and passed once through the microfluidizer.
The glyburide-containing composition may be made
into microcapsule formulations using the Spherex TRN, or
made into a powder using the Spir-A-Flow, or stored in a
dark brown glass bottle at cool temperature (as in
Example 1). If microcapsules are made (as, for example,
in Example lA), each microcapsule or hard gelatin capsule
containing the powder preferably has about 0.5 mg active
glyburide per 5 ml or 125 mg of the microcapsules.
Example 3
An insulin-containing composition of the present
invention may be prepared as in Example 1 above. After
carefully blending and mixing glyburide together with one
or more inert chemicals, e.g. IiPC, CMC-Ca, alginate, or
gelatin, the mixed powders are placed into the chamber of
the Spir-A-Flow and dried at 27-29°C. The insulin-
containing solution of Example 1 is then spray coated
over the inert.chemical mixture. The dried powder of
insulin plus glyburide -composition is packed into #1
sized capsules, with each capsule containing 8 units of
insulin, and 0.5 mg of glyburide.
In the alternative, the insulin-containing
composition of Example 1 and the glyburide-containing
composition of Example 2 are mixed in such manner as to
yield 8 units of insulin and o.5 mg of glyburide per
capsule, and the mixed solutions are spray coated over
R'O 95112385 _ PCT/US94/12351
-44-,
the inert chemicals by using the Spir-A-Flow; or the
mixed solutions may be packed into soft gelatine capsules
and may thereafter be orally administered.
Example 4
Urokinase (uPA) available from Novabiochem Ltd. and
having a makeup of 90% high molecular weight (i.e. about
54,000) and 10% low molecular weight (i.e. about 33,000)
is dissolved in a sodium phosphate buffer solution having
a pH of about 7.4, and mixed with about 0.05-2,
preferably 0.5 mg GPC and 0.05-2, preferably 0.5 mg of
GPA, in a water bath at a temperature of 37-38°C. Lyso-
PC is then added in amounts of 0.005-0.1, preferably 0.04
mg, in the presence of 800-17,600, preferably about 888
KIU of aprotinin, and polyoxy-40-stearate, with the
stearate present in amounts of 0.05-5, preferably 1.2
v/v% (of the final volume of hydrophilic phase) at room
temperature; 0.9-3.6, preferably 1.4 mg of water soluble
cholesterol; and 1.8-9.0, preferably 1.4 mg of PC are
dissolved in about half of the final volume of MCT used
in the presence of sorbitan trioleate, present in amounts
of 0.01-4, preferably 0.5% of the final volume of
lipophilic phase. The above hydrophilic and lipophilic
solutions are mixed, homogenized and passed through a
microfludizer (for example, manufactured by Microfludics
Co. of Newton, Mass.), at a shear force of 60,000-80,000
psi with cooling for 2-3 min.; 0.15-15, preferably 0.8
v/v% glyceromonooleate/oleic acid solution and 0.5-2.5,
0.88 mg d-alpha-tocopherol are added to oleic acid
solution, which is present in amounts of 0.5-5.0,
preferably 4.5 w/v% of the final volume of the above
lipophilic & hydrophilic phase solutions and then made up '
to a total volume of 20 ml by adding MCT, and micronized
again at a shear force of 6,000-8,000 psi with cooling
for another 2-3 minutes. The yield solution may be
stored in a dark brown bottle at 2-4°C. Alternatively,
the resultant solution may be made into microcapsules by
WO 95112385 PCT/US94/12351
-45-
conventional means, for example using the Spherex TRS as
described above.
Example 5
18,000 - 24,000, say 20,000 KIU aprotinin is added
to 1.6-2.0 say l.8gm of bovine insulin and dissolved,
adjusting its pH to about 2.2-3.0, say 2.4 by adding
saturated sodium citrate solution). About 0.2mM calcium
chloride, 8.6-12.3, say 10.7 gm of water soluble
cholesterol, about 5.9-8.6 say 7.6 gm of GPC, about 2.2-
5.2, say 3.9 gm of GPS, about 0.6-1.2, say 0.8 Mg of
lyso-PC, and about 4.6-7.8, say 6.0 gm of polyoxy-40-
stearate are dissolved in about 50 ml of ethanol. About
0.2-0.9, say 0.4 gm of Hydroxypropylcellulose (HPC) is
slowly but properly dissolved at room temperature in 10
ml of deionized water. All of the above solutions are
mixed, and its final volume is made up to 7o ml by adding
ethanol, mixing and homogenizing. Ten ml of 0.9%
physiological solution, as a commercial form of TRASYLOL-
TM, contained 100,000 KIU of aprotinin (Bayer).
PC, ranging from 0.1-1.2 preferably o.25 gm, is
dissolved in 10 ml of MCT oil. The above mixture is
added to the PC-containing MCT solution and homogenized.
To this MCT solution, d-alpha-tocopherol (preferably at
2.5-4.8, say 3 v/v% of the final volume of products) is
mixed and its final volume is made up to 100 ml by adding
50% of an MCT:ethanol solution (ethanol, 99% is used).
The admixed solutions are homogenized and ultramicronized
by using the Nanomizer. Sodium salicylate at
concentration of 0.04-0.12 mg, say 0.08 mg per 5 ml of
the final product, dissolved in glycerol (1:4 solution)
is added to the final product and homogenized.
The above TuD-Insulin solution contains about 14-20,
say 16 IU of bovine insulin per drop. Usually one to
three (preferably 2) drops of TuD-Insulin is placed on
the navel. About 20-24, say 22 drops of the TuD-insulin
is one ml.
WO 95/12385 PCT/US94/12351
21'75491
-46-
Example 6:
Trans-Umbilico-Dermal Drug Delivery System
(For phvsost~amsnel
For cognitive therapy, physostigmine infusion may
improve transitory cognitive functions, while ergoloid
mesylates (e. g.. Hydergine-TM) may improve the subjective
cognitive functions. An intermittent dosing of
fluoxetine, thioridazine, diphenhydramine, and other
neuropharmacologics in combination may improve the
noncognitive behavioral symptoms. Most of these drugs
can be effectively given orally. However, physostigmine
must be parenterally given to be effective.
Physostigmine salicylate injection (USP) is available (pH
4-6; 90-110.0% solution); 0.5-1.0 mg repeated per 0.5-1.0
hour-intervals (for management of over dosage of
Anticholinergia or post anesthesia).
A TuD formulation for physostigmine has been
designed. TuD-physostigmine may eliminate for the need
of frequent intravenous or intramuscular injections.
Physostigmine, to make 0.06-0.12 mg, preferably
0.1 mg per drop, is added into GPC (0.8-3.0; preferably
0.8 gm), lyso-PC (0.55-10; preferably 6 mg), polyoxy-40-
stearate (3.2-24.4; preferably 12.2gm) in MCT (5-8 gm).
After homogenizing the solution, sodium salicylate (0.04-
0.12; preferably 0.08 mg dissolved in 1:4 glycerol per 5
ml of the final product) is added. It is made up to 40
gm with MCT, made up to the final volume of 50 gm with
99% ethanol, rapidly homogenized, and micronized at cold
temperature. If possible, physostigmine and its
contained TuD formulation should not be exposed to light.
It should be stored in a dark glass, at cool temperature.
An antioxidant (d-alpha-tocopherol, about 0.5% of the
final product) may also be added.
W0 95112385 PCT/US94/12351
-47-
Fxamvle I (Clinical Studv)
Two IDDM and 3 NIDDM patients, 4 males and 1 female,
aged between 42-59 years old, were studied. After
overnight fasting, at 6:00 a.m. of the study day, 32u of
insulin as in Example lA were orally given and the blood
sugar as well as serum insulin level were measured hourly
for 3 hours (under fasted conditions). The results are
set forth belovi:
Age 8 0o Sugar (mMoi L) Serum Inauhn (uU m )
Pt.~ & Class
Sex 0 1 ~ 1 3
ERAMPLE - INSULIN MICROCAPSULE Units)
in (3
1 S9M NIDDM 11.29.5 7.D 6.2 20 60 73 56
2 54F NIDDM 10.48.3 7.9 6.5 26 41 64 -
4 46M NIDDM 9.8 9.2 8.5 5.9 27 64 72 40
5 42M IDDM 12.712.0 9.2 7.9 11 16 47 29
6 43M IDDM 10.99.8 8.3 6.6 14 21 52 50
Mean 48. 11.0 9. . .6 19.6 4 . 61.6 43.8
Therapeutically significant reduction in the blood
glucose levels were observed after the administration of
microcapsule-insulin compositions of the present
invention prepared in accordance with Example 1A, with
the maximum effects observed at 3 hours after the dosing,
and a gentle elevation in the serum insulin level,
peaking at 2 hours after the medication, was also
observed. The microparticle-bound insulin suspended in
MCT micelle composition of this invention was thus shown
as an effective oral formulation for lowering the blood
sugar while moderately elevating the serum insulin in
diabetic patients.
Examples II & III (Clinical Studies)
A group of NIDDM, who were previously known as non-
responsive to oral glyburide (or other oral hypoglycemic
agents) and were receiving parenteral injections of
insulin as well, were selected and studied after
overnight fasting. On the early morning of the Study Day-
W095I12385 . PCT/US94112351
-48-
1, the NIDDM patients were orally given the insulin-
containing (32 Units) and glyburide-containing
composition (2.0 mg) of Example 3. The blood sugar
levels were measured at times 0, 1, 2, 3, and 4 hours
after the medication, and the serum insulin levels were
measured by a radio immunoassay method from the blood
samples collected at times 0, 1.5 and 3.0 hours of the
study. After one day of washout period, on the Study Day-
3, a study similar to those ofthe Study Day-1 was
repeated after an oral administration of the glyburide
containing composition (2.0 mg) of Example 2 above.
In these glyburide-resisting NIDDM patients,
the glyburide-containing composition (Example 2) caused a
marked reduction in the blood sugar level, modified 2-
hour post-prandial blood sugar levels, moderately
elevated serum glyburide and insulin levels (see Figure
1), while after the insulin-containing plus glyburide-
containing (Example 3) composition, a significant
antihyperglycemic effect normalizing the 2-hour post-
prandial blood sugar levels, marked elevation in the
serum glyburide level and significant elevation in the
serum insulin levels were observed (as shown in Figure
2). A combination of the insulin-containing and the
glyburide-containing compositions thus restored the
activities of glyburide in these glyburide-resisting
NIDDM patients, as would be the case with parenteral
injections of insulin.
Example IV (Clsns~al s+»~~.o _
A group of healthy volunteers participated in this
study. After an overnight fasting, about 34,000 U of a
composition of this invention comprising uPA as the
pharmaceutically-active agent prepared as described in
Example 4 was given orally at 10-minute intervals for
three consecutive doses (a total of 102,000 U of the uPA-
containing composition) for 3 consecutive days, while
plasma levels of uPA (measured by ELISA assay and FDP
WO 95/12385 PCT/US94/12351
d,,' . .
~~ -49- '
agglutination test) were measured and compared against
the effects observed after intravenously infusing 50,000
U of uPA in the same subjects. The uPA.was infused over
150 minutes on Day-1, Day-2, and Day-3 of the study.
FDP assay was used as an indicator for the
bioactivity of uPA. Detection and semi-quantitative
analyses of fibrinogen degradation products (FDP) was
accomplished by agglutination of latex particles coated
with specific antibodies (from Diagnostica Stago of
France). Enzyme immunoassay for the detection of human
urokinase (uPA) antigen in plasma was based on the double
antibody principle, using two different monoclonal
antibodies by the ELISA method (American Diagnostics,
U.S.A.).
As shown below, 100,000 U (34,000 U given every
10 min for three times) of the uPA-containing composition
of this invention (Example 4), orally given for 3
consecutive days, was bioavailable and bioactive, and
achieved better results in terms of effects observed than
the corresponding treatment of 50,000 U of uPA infused
for 3 consecutive days in the same subjects.
WO 95112385 PCT/US94/12351
-50-
ELISA ANALYSIS AND FIBRIN DEGRADATION PRODUCTS (FDP)
AGGLUTINATION TEST OF PLASMA SAMPLES AFTER ORAL AND
INTRAVENOUS uPA IN VOLUNTEERS (N=4 Males)
Hours 0 6 12 24 32 48 54
ELISA ANALYSIS (Units=O.D.at 405 x 1/10)
EXAMPLE-4-uPA (102,000 IU on Time-0, Time-24, and
Time-48)
Mean 32 68 58 66 64 66 69
Intravenous Infusion of uPA (50,000 IU on Time-0, T me-
24, and Time 48)
Mean 35 54 38 34 62 31 59
FDP AGGLUTINATION TEST (Graded as +1, +2, and +3;
Readings x 1/10)
EXAMPLE-4-uPA (102,000 IU on Time -0, Time -24, and Time-
48)
Mean 6 20 25 18 27 20 27
Intravenous Infusion of uPA (50,000 IU on Time-0, Time-
24, and Time-48)
Mean 6 16 10 6 18 13 22
***the Grades for the FDP Agglutination Test are SCORED
as 0, 0.25 (read as 0.3), 0.5, 0.75, (read as 0.8), 1.0,
1.25 (read as 1.3), 1.5, 1.75 (read as 1.8), 2.0, 2.25
(read as 2.3), 2.5, 2.75 (read as 2.8), and 3.0
Example V
(Clinical Study of the Trans-Umbilico-Dermal
Delivery of rnsL~in Tn Di-hoti~~)
Five male diabetics, 2 IDDM and 3 NIDDM, of ages
between 28-56 (mean of 43.6) years old participated in
the study. After an overnight fasting, and after
measuring the blood glucose and serum insulin levels at
Time-0, 2 drops (about 32 U) of insulin of the insulin-
containing composition of 'the present invention prepared
as described in Example 6 was applied, i.e. dripped on
the patients~ navel, and the blood sugar and serum
insulin levels were measured, hourly, for 2 to 3 hours.
As shown in the table below, the blood glucose level
of about 10.3 mMol/L at Time-0 was decreased to about 7.5
SUBSTIME SHEET {RULE 26)
wo 95II238s . PCT/US94I123s1
-51-
mMol/L within one hour, and was reduced further to
5.5 mMol/L at Time-3 hours. A correspondingly high serum
level of insulin was also observed. Thus, the insulin-
containing composition of Example 5 has been demonstrated
to be an effective and bioavailable therapeutic agent in
diabetics when employed via trans-umbilical-dermal
administration: i.e., the onset of action was faster than
that of an oral administration of the insulin-containing
composition of this invention as in Example 1.
TRANB-Ub7BILICAL-DERM11L ADNINIBTRATION
Age & Body Blood Glucose (m/ML) Serum Insulin-uU/ml
Case Sex Class Weight
(Kg) 0 1 2 3 (Hrsy
1 28M IDDM 54 9.8 5.6 7.0 5.8
2 33M IDDM 48 10.2 8.5 6.8 4.8
3 56M NIDDM 65 9.8 6.9 5.6 5.0
4 52M NIDDM 79 11.0 8.3 7.2 6.0
5 49M NIDDM 62 10.5 8.0 6.9 5.7
Mean 43.6 61.6 10.3 7.5 6.7 5.5
serum Insulin uU/ml
1 14 66 73 43
2 19 71 61 60
3 28 96 78 48
4 - 92 82 72
5 22 78 60 66
Mean 20.8 80.6 70.8 57.8
Example VI
Augmented Targeted Delivery
of Cancer ChemotheranP"tics
Based on the Goldie-GOldman~s hypothesis, a
permanent drug resistance may occur in tumor cells as a
result of random genetic mutations at a rate of, say, one
in 1 million cells. In a minimally detectable size of
SUB$TI'FlJIE SHEET (fBULE 26~
WO 95112385 . PCT/US94/12351
52
tumor having about 1,000 million cells, it may already
have formed one or more resistance cell lines. Thus,
multidrug regimens are useful in overcoming resistance by
the cancer cells to a chemotherapeutic agent, and it is
important to initiate the combination drug therapy as
early as possible. Furthermore, it is important to
saturate the cancer cells with the known effective
chemotherapeutic agents in combination, while reducing
any undesirable side effects.
The compositions of this invention, comprising
various,pharmaceutically-active agents, are believed to
be useful in augmenting the therapeutic indices of some
of the well known cancer chemotherapeutics, whose toxic
or severe side effects are well known and documented.
In one embodiment, vincristin-containing
formulations of this invention for parenteral or trans-
umbilico-dermal administration in cancerous patients may
be made in accordance with the method of this invention
as follows: ten mg of vincristin, admixed in 1 gram of
manitol, 13 mg of methylparaben, and 2 mg propylparaben
in acetic acid/sodium acetate containing water to make
10 ml, with a pH of 3.5-5.5 was prepared. This mixture
was added and dissolved into 0.5 mg GPS, 1.4 mg GPC, 0.8
mg lyso-PC, 1.5 mg of water soluble cholesterol, and 2.2
mg polyoxy-40-stearate, and the resultant mixture was
micronized at room temperature. 5 grams of
glyceromonooleate dissolved in MCT and the above
vincristin-containing solution were admixed. A
sufficient quantity was added of the vincristin solution
and MCT to yield about 0.5 mg of vincristin per ml of the
final product, and the final solution was microfluidized
at room temperature and filtered. This composition may
be administered paraneterally, trans-umbilico-dermally,
or orally.
The vincristin-containing composition of this
invention, as described above, in an intraperitoneal
WO 95112385 PCT/US94/12351
-53-
injection, was found effective in prolonging the survival
times in the P388 mouse leukemia model. The P388 mouse
leukemia model was prepared according to the method
described by Daoud and Juliano in Cancer Res. 48: 5518
(1986). Female mice were intraperitoneally inoculated
with P388 mouse leukemia (1 million cells/0.1 ml) on
Study Day-0. The study drugs were intraperitoneally
injected on Study Day-1. The mortality was monitored
daily, and the mean survival times of mica treated with
vincristin (1.25 mg/kg), mice treated with the
vincristin-containing composition of this invention (1.25
mg/kg) (referred to as the Targeted Drug Delivery System
or TDDS) vs. the control group receiving 0.1 ml/10 g of
0.9% NaCl solution, were studied. The results were as
follows:
MEAN SURVIVAL TIME OF TREATED VS. CONTROLLED LEUKEMIC MICE
Group Mean SEM
Control 14.6 2.9 (days)
Vincristin (1.25 mg/kg) 21.2 4.1
TDDS-Vincristin 42.0 6.g
For the tumor model, a group of Wister rats were
inoculated subcutaneously with 100,000 IgM immunocytoma
cells in 0.5 ml of plain RPMI 1640 medium (from the Grand
Island Biological Co.), and when the tumor diameter was
about 20 mm or more in size within 6 days, the rats were
used for the study. Reduction in the size of tumor mass
for both treated and control rats, as % changes in the
tumor size were measured, and summarized as follows:
REDUCTION IN TUMOR VOLUME IN RATS (%)
V~ncristsn TDDS-Vincr~st~n
Conc. 1.25 mg/kg 1.25 mg/kg
Mean 11.5 34.7
SEM 8.6 10.3
WO 95112385 PCTIUS9~112351
~1't5g~94
As demonstrated above, the vincristin-containing
composition of this invention apparently was
preferentially absorbed by the tumor and leukemic cells
of experimentally induced -cancerous rats and leukemic
5 mice. The therapeutic efficacy of vincristin was
significantly increased by its use as a pharmaceutically
active agent in the TDDS embodiment of this invention.
The compositions of this invention may be used to
treat a number of conditions or in various therapeutic
regimens. For example, in one preferred embodiment, the
compositions of this invention may be employed in a
method of treating diabetes. In another preferred
embodiment, such compositions may be used in a method of
antibiotic therapy. In yet another embodiment, such
compositions may be employed in methods of cancer
treatment or chemotherapy. In yet another embodiment,
such compositions may be employed in hormonal or
antiparasitic agent therapy.
It should be understood that various changes and .
modifications to the preferred embodiments described
herein will be apparent to those skilled in the art.
Such changes and modifications can be made without
departing from.the spirit and scope of the present
invention and without diminishing its attendant
advantages. It is therefore intended that such changes
and modifications be covered by the appended claims.
